Human identification is widely used in forensics, paternity testing, disaster victim identification, and anthropology, among other applications, with DNA analysis/profiling being a key tool in this sector. Due to increasing demands on time and resources, human identification and forensics labs are under constant pressure to increase the efficiency of their workflows without sacrificing quality. Examining the variety of biological indicators that are available to investigators illustrates the basic principles of each process in criminal investigation and paternity identification. While DNA and fingerprints are clearly the favored methods of identification, they require a prior record and verifiable baseline for comparison. Further remarkable advancements in the field of genomics, proteomics, molecular biology, data analytics, and technical engineering have paved the way for the development of advanced NGS-based technologies, such as SNP and STR sequencing. The impressive research on molecular technologies and biomarkers using NGS has unlocked pathways for the development of various momentous procedures such as mtDNA sequencing.
The growing demand for non-invasive diagnostic procedures enabling genetic profiling has further enhanced the requirement for NGS technologies. Acknowledging the future potential for massive growth in demand for noninvasive diagnostic procedures, several biotechnology companies such as Illumina, Inc., Thermo Fisher Scientific, and Agilent Technologies, Inc. have invested substantially to aid further developments in forensics technologies.
Human Identification Market is projected to reach $6,435.6 million by 2032 from $1,385.8 million in 2021, at a CAGR of 14.77% during the forecast period 2022-2032.
The growth in the global human identification market is expected to be driven by the increasing adoption of NGS in various research fields, high adoption of forensic applications, and technological advancements in the field of molecular techniques and diagnostics tests.
Market Drivers
Increasing Demand for Human Identification Products/Technologies
Due to the ever-rising forensic cases, the need for better products and services is becoming more evident. Several key players are aligning their technologies as per the market requirements to provide technologically advanced products and services by adopting inorganic strategies such as product launches. The Federal Bureau of Investigation reported that violent crime fell nationwide in the period from 2015 to 2020. During crime reporting, the FBI's Uniform Crime Reporting Program considered murder, forcible rape, and aggravated assault to be violent crimes because they are offenses that involve force or threat of violence.
Action Required: Download the Free Sample and Unleash the Power of the Human Identification Market
Get Flat 15% Discount on Report Purchase - Use Code : SUMMER23
Some of the prominent names established in this market are:
• Abbott.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Eurofins Scientific
• Promega Corporation
• Illumina, Inc.
• Laboratory Corporation of America Holdings
• PerkinElmer Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• Verogen, Inc.
• NMS Labs
• AUTOGEN INC.
• GENETEK BIOPHARMA GmbH
• SecuriGene Technologies Inc.
Key Questions Answered in the Report
▪ What are the major market drivers, challenges, and opportunities in the global human identification market?
▪ What are the key development strategies which are implemented by the major players to sustain in the competitive market?
▪ Which is the dominant product type developed by the leading and emerging players for human identification?
▪ How is each segment of the market expected to grow during the forecast period from 2022 to 2032?
▪ Which companies are anticipated to be highly disruptive in the future, and why?
▪ From the end-users' point of view, does efficiency or convenience hold the key to driving the global human identification market?
Additionally, BIS Research also offers a dedicated and unique platform to find and access deeptech insights and updates on emerging technologies across industry verticals. Insight Monk, an AI powered deeptech search engine, is a subscription based platform that offers a library of latest market insights and updates based on emerging tech. Learn more about InsightMonk here.
Be the first person to like this.
In recent years, gene editing technologies have emerged as a promising tool for treating a variety of genetic disorders. These technologies have the potential to not only cure genetic diseases but also to enhance human abilities, modify food crops, and create new species altogether. However, as with any powerful tool, gene editing also raises ethical and social questions. In this blog, we will explore the various gene editing technologies and their potential applications, as well as the ethical and social implications of their use.
What is Gene Editing?
Gene editing is the process of making specific changes to the DNA sequence of an organism. These changes can be made in two main ways: by adding, deleting or replacing genes, or by modifying the expression of existing genes. Gene editing technologies enable precise and targeted modifications of the genetic code, which allows for more efficient and accurate modification of an organism's traits.
Gene Editing Technologies
There are several gene editing technologies currently in use, with each having its own strengths and weaknesses. The most popular gene editing technologies are:
CRISPR-Cas9: CRISPR-Cas9 is a genome editing system that uses a small RNA molecule to guide a protein called Cas9 to a specific location in the genome. Once at the target site, the Cas9 protein cuts the DNA, allowing researchers to add, delete, or replace specific genes. The CRISPR-Cas9 system is widely used because of its ease of use, low cost, and high efficiency.
TALENs: Transcription activator-like effector nucleases (TALENs) use a similar approach to CRISPR-Cas9. However, TALENs use a different protein to cut the DNA. While TALENs are less efficient than CRISPR-Cas9, they have been shown to work in a wider range of organisms.
Zinc-Finger Nucleases (ZFNs): Zinc-finger nucleases (ZFNs) are similar to TALENs in that they use a different protein to cut the DNA. ZFNs are less efficient than CRISPR-Cas9, and they are more difficult to design and manufacture.
Applications of Gene Editing Technologies
Gene editing technologies have the potential to revolutionize medicine, agriculture, and many other fields. Some potential applications include:
Treating genetic diseases: Gene editing can be used to correct genetic mutations that cause diseases like cystic fibrosis, sickle cell anemia, and Huntington's disease. Researchers are also exploring the use of gene editing to treat cancer by modifying immune cells to recognize and attack cancer cells.
Enhancing human abilities: Gene editing could be used to enhance human abilities, such as improving memory or increasing intelligence. However, such applications raise ethical questions about creating a "superior" class of humans.
Modifying food crops: Gene editing can be used to modify food crops, making them more resistant to pests and diseases or more nutritious. However, the use of genetically modified crops raises concerns about the potential environmental impact and the safety of consuming these crops.
Creating new species: Gene editing can be used to create new species, such as mosquitoes that cannot carry malaria or plants that can grow in harsh environments. However, creating new species raises ethical questions about the potential impact on ecosystems and the potential unintended consequences of releasing genetically modified organisms into the wild.
Gene Editing Technologies Market Overview
Gene editing technologies are rapidly transforming the healthcare industry and have become a major focus of research and development in recent years.
According to BIS Research, the Gene Editing Technologies Market was valued at $1.81 billion in 2022 and is anticipated to reach $16.37 billion by 2032, witnessing a CAGR of 27.50% during the forecast period 2023-2032.
The market is expected to grow due to the increasing prevalence of genetic disorders, rising demand for personalized medicine, and advancements in gene editing technologies. The market is segmented based on technology, application, end-user, and region. The CRISPR-Cas9 technology dominates the gene editing technologies market, but other technologies such as TALEN and ZFN are also gaining popularity. The market is further segmented by application, including genetic engineering, cell line engineering, and others. End-users of gene editing technologies include biotechnology and pharmaceutical companies, academic and research institutes, and contract research organizations. North America dominates the gene editing technologies market, followed by Europe and the Asia Pacific. The major players in the gene editing technologies market include Thermo Fisher Scientific, CRISPR Therapeutics, Editas Medicine, Sangamo Therapeutics, and Horizon Discovery Group. The market is expected to continue to grow rapidly due to increasing investment in research and development, growing demand for personalized medicine, and increasing collaborations between academic institutes and pharmaceutical companies.
Get Free Sample Report - Click Here
Key Questions Answered in the Report
What are the three potential scenarios in which the global gene editing technologies market growth can unfold during 2022–2032?
What are the key trends influencing the global gene editing technologies market, and what is their potential for impacting the market?
What is the patent landscape of the global gene editing technologies market like? Which year and country witnessed the maximum patent filing between January 2018 and December 2022?
What are the key regulations that impact the growth of the global gene editing technologies market?
Be the first person to like this.
In an era defined by rapid technological advancements, staying ahead of the curve is crucial for businesses to thrive. Deep Tech Market Intelligence Reports offer a valuable resource that sheds light on emerging technologies, trends, and market opportunities. These comprehensive reports provide businesses with the insights they need to make informed decisions, anticipate market shifts, and harness the potential of deep tech innovations. Join us as we delve into the world of Deep Tech Market Intelligence Reports and discover how they can shape the future of businesses.
Insight Monk is an industry-leading platform that specializes in deep tech market intelligence. Leveraging advanced analytics, machine learning algorithms, and a team of domain experts, Insight Monk provides businesses with unparalleled access to valuable insights and data-driven strategies. It equips organizations with the tools needed to thrive in the competitive deep tech landscape. Over 1000 deep tech market research reports are available, covering multiple industries and with 5-10 year forecasts.
Verticals Covered on the Platform
Advanced Materials, Chemicals, and Fuels
Aerospace
Agriculture
Automotive/Mobility
Healthcare
Defense and Security
Digital Technologies
Electronics and Communication Technologies
Energy and Power
Foodtech
Robotics and Automation
The Power of Deep Tech
Deep Tech, also known as frontier technology, encompasses cutting-edge innovations such as artificial intelligence, robotics, blockchain, nanotechnology, and more. We explore how these technologies have the potential to revolutionize industries, disrupt traditional business models, and unlock new possibilities. By understanding the vast scope of deep tech, businesses can gain a competitive edge and identify areas for growth and investment.
Navigating the Complex Landscape
The realm of deep tech is constantly evolving, making it challenging for businesses to stay informed about the latest advancements and market dynamics. Deep Tech Market Intelligence Reports act as a compass, providing comprehensive insights into technology trends, market size, competitive landscapes, regulatory frameworks, and investment opportunities. We delve into the importance of these reports in helping businesses navigate the complex deep tech landscape and make strategic decisions.
Harnessing Market Insights
Deep Tech Market Intelligence Reports offer a treasure trove of information that can shape business strategies. We explore how these reports provide an in-depth analysis of market segments, emerging technologies, and consumer behavior. By leveraging these insights, businesses can identify untapped markets, optimize product development, refine marketing strategies, and position themselves as industry leaders.
Future-proofing Business Strategies
The pace of technological disruption demands that businesses adapt and innovate continually. Deep Tech Market Intelligence Reports offer a glimpse into the future, enabling businesses to anticipate market shifts, identify potential risks, and seize opportunities before their competitors. We delve into real-life case studies where businesses have utilized these reports to stay ahead of the curve and successfully navigate industry disruptions.
Collaborating and Networking
In addition to providing market insights, Deep Tech Market Intelligence Reports facilitate collaboration and networking opportunities. We explore how businesses can connect with industry experts, startups, investors, and research institutions through these reports, fostering innovation, partnerships, and knowledge exchange.
Explore Deep Tech Market Intelligence Reports at: Click Here
Conclusion
Deep Tech Market Intelligence Reports serve as a compass for businesses, guiding them through the complex and ever-evolving landscape of emerging technologies. By leveraging these reports, businesses can gain valuable insights, anticipate market trends, and make informed decisions that will shape their future success. In a world where staying ahead is paramount, embracing deep tech intelligence reports is an investment in the growth and sustainability of businesses in the digital age.
Be the first person to like this.
In the rapidly evolving landscape of technology, staying ahead of the curve is crucial for businesses seeking growth and innovation. The deep tech market, characterized by groundbreaking advancements in fields like artificial intelligence, blockchain, robotics, and quantum computing, presents tremendous opportunities and challenges. To navigate this complex terrain, organizations need access to accurate, up-to-date, and actionable market intelligence. Enter Insight Monk—a cutting-edge platform revolutionizing the way businesses harness the power of deep tech market intelligence.
Deep tech market intelligence refers to the comprehensive understanding of emerging technologies, market trends, competitive landscapes, and investment opportunities within the realm of deep tech. It empowers businesses to make informed decisions, identify growth prospects, mitigate risks, and drive innovation. With the ability to analyze vast amounts of data, uncover hidden insights, and provide actionable recommendations, deep tech market intelligence is a game-changer for organizations operating in this highly dynamic sector.
Introducing Insight Monk
Insight Monk is an industry-leading platform that specializes in deep tech market intelligence. Leveraging advanced analytics, machine learning algorithms, and a team of domain experts, Insight Monk provides businesses with unparalleled access to valuable insights and data-driven strategies. It equips organizations with the tools needed to thrive in the competitive deep tech landscape.
Key Features of Insight Monk
Comprehensive Research: Insight Monk's team of experts conducts in-depth research to gather and analyze data from a wide range of sources. This includes monitoring scientific papers, patents, industry reports, startup databases, and more. The platform ensures that businesses have access to the most up-to-date and relevant information available.
Trend Analysis: By employing advanced data analytics techniques, Insight Monk identifies emerging trends within the deep tech market. From advancements in quantum computing to breakthroughs in biotechnology, businesses gain valuable insights into the direction of the industry, enabling them to anticipate market shifts and adapt their strategies accordingly.
Competitive Intelligence: Insight Monk provides a detailed analysis of the competitive landscape, offering businesses a comprehensive understanding of their rivals. This includes tracking competitors' product launches, partnerships, and investment activities. Armed with this knowledge, organizations can make informed decisions and gain a competitive edge.
Investment Opportunities: Insight Monk uncovers promising investment opportunities within the deep tech sector. By monitoring startups, venture capital activity, and funding rounds, the platform identifies high-potential companies, enabling investors to make strategic investment decisions.
Customized Reports and Alerts: Insight Monk delivers tailored reports and real-time alerts to its users. Businesses can customize their preferences to receive updates on specific technologies, markets, or companies of interest. This feature ensures that decision-makers stay informed about the latest developments relevant to their organization's goals.
Conclusion
In the era of deep tech, having access to accurate and timely market intelligence is essential for organizations striving to thrive and innovate. Insight Monk serves as a reliable partner, offering deep tech market intelligence that empowers businesses to make informed decisions, identify growth opportunities, and stay ahead of the competition. By harnessing the power of advanced analytics and expert insights, Insight Monk paves the way for success in the dynamic and ever-evolving deep tech market. Embrace the transformative capabilities of Insight Monk and unlock the full potential of deep tech market intelligence for your organization.
Be the first person to like this.
Genomic sequencing is a method of determining the genetic makeup of an organism. Sequencing technologies have undergone several advancements in the past decade as researchers aim to improve the throughput and accuracy of base calling while also reducing costs.
Next-generation sequencing (NGS) is a massively parallel sequencing technology that is capable of sequencing millions of deoxyribonucleic acid (DNA) fragments simultaneously. The NGS workflow involves library/sample preparation followed by sequencing and data analysis. NGS has a wide range of applications, such as aiding in the diagnosis of various clinical conditions, automation of the NGS workflow, genetic screening, and selecting candidates for clinical trials. Moreover, NGS is also finding applications in areas beyond healthcare, such as in assessing the authenticity of food items, i.e., checking for cheaper substitutions of substances in food.
NGS informatics market was valued at $1,380.0 million in 2021 and is projected to reach $6,715.0 million by the end of 2032. The market is expected to grow at a CAGR of 15.21% during the forecast period 2022-2032.
The market is driven by factors such as the low cost of sequencing platforms, increasing clinical applications of NGS in the field of oncology for the clinical management of cancer patients and mutation profiling, a tremendous rise in the amount of genomic data, the growing importance of population genomics studies and the establishment of various biobanks, advancements in big data technology, and government initiatives to support the advancement of NGS are expected to lead to higher demand for NGS informatics software.
Market Lifecycle Stage
The global NGS informatics market is in the development phase. The evolving regulatory landscape for clinical NGS and the growing number of gene mutations across various diseases are some of the major opportunities in the global NGS informatics market.
Market Segmentation Based on Products and Services
The global NGS informatics market has been segmented into software solutions intended for storage and computing, tertiary data analysis, and automation and automating NGS workflows in laboratories, as well as NGS services such as sequencing services or consulting organizations in automating their NGS workflows
Market Segmentation Based on Application
The advantages of NGS, such as its high sensitivity, quantitative nature, high dynamic range, and lack of hybridization, make it suitable for drug discovery. NGS has been used in the various steps of drug discovery, such as target identification and screening of compounds. NGS also plays a key role in the identification of rare variants responsible for various diseases. Detecting these variations in individual genomes helps identify the best course of treatment that will be effective for an individual and allows a greater number of targeted genes to be added to the testing panel.
Regional Analysis
Regions such as North America and Europe have a technologically advanced healthcare and genomics landscape, due to which these regions hold the maximum share in the global NGS informatics market. Regions such as Asia-Pacific, Latin America, and Rest-of-the-World are anticipated to register significant growth during the forecast period 2022-2032 owing to factors such as the rigorous research and development (R&D) related to NGS, advancements in big data technology, and increasing clinical applications of NGS in cancer.
Get a Free Sample Report - https://bisresearch.com/requestsample?id=1417&type=download
Some prominent established names in this market are:
• Abbott Laboratories
• Agilent Technologies, Inc.
• Azenta, Inc.
• BGI Genomics Co., Ltd.
• DNAnexus, Inc.
• Eagle Genomics
• Euformatics
• F. Hoffmann-La Roche Ltd.
• Genalice BV
• Illumina, Inc.
• Partek Incorporated
• PerkinElmer, Inc.
• Precigen, Inc.
• QIAGEN N.V.
• SOPHiA GENETICS SA
• Thermo Fisher Scientific Inc.
Additionally, BIS Research also offers a dedicated and unique platform to find and access deeptech insights and updates on emerging technologies across industry verticals. Insight Monk, an AI powered deeptech search engine, is a subscription based platform that offers a library of latest market insights and updates based on emerging tech. Learn more about InsightMonk here. https://www.insightmonk.com
Be the first person to like this.
Cell-based assays are powerful tools used in the pharmaceutical, biotechnology, and academic research fields to investigate various biological processes. These assays are designed to study the interaction between drugs or other chemical compounds with living cells. The information obtained from cell-based assays is critical for drug discovery, toxicity screening, and basic research. In this blog post, we will discuss cell-based assays in detail, including their types, advantages, and limitations.
What is a Cell-Based Assay?
A cell-based assay is a test that evaluates the effect of a chemical compound on living cells. The assay can measure various cellular processes, such as proliferation, apoptosis, differentiation, migration, and gene expression. Cell-based assays can use different types of cells, including primary cells, immortalized cell lines, and stem cells. These assays can be performed in vitro or in vivo, depending on the research question.
Types of Cell-Based Assays
Cell-based assays can be divided into three main categories based on the readout method: endpoint assays, kinetic assays, and imaging assays.
Endpoint Assays
Endpoint assays measure the effect of a compound on the cells at a specific time point. The readout can be quantitative or qualitative. Examples of endpoint assays include cell viability assays, cytotoxicity assays, and ELISAs.
Kinetic Assays
Kinetic assays measure the effect of a compound on the cells over time. The readout can be continuous or intermittent. Examples of kinetic assays include real-time PCR, flow cytometry, and calcium imaging.
Imaging Assays
Imaging assays use microscopy to visualize the effect of a compound on the cells. The readout can be qualitative or quantitative. Examples of imaging assays include fluorescent microscopy, confocal microscopy, and high-content screening.
Advantages of Cell-Based Assays
More relevant to human biology: Cell-based assays use living cells, which better mimic human biology than isolated proteins or enzymes.
High throughput: Cell-based assays can be performed in 96- or 384-well plates, allowing for high-throughput screening of large compound libraries.
Versatility: Cell-based assays can measure a wide range of biological processes, making them useful for drug discovery, toxicity screening, and basic research.
Cost-effective: Cell-based assays are generally more cost-effective than in vivo assays and require fewer animals.
Reduced ethical concerns: Cell-based assays reduce the need for animal testing, which is a significant ethical concern.
Limitations of Cell-Based Assays
Variability: Cell-based assays can have high variability, which can make data interpretation challenging.
Complex data analysis: Cell-based assays generate large amounts of data that can be difficult to analyze without advanced computational tools.
Reproducibility: Cell-based assays can be challenging to reproduce, especially when using primary cells or stem cells.
Limited tissue penetration: Some cell-based assays cannot penetrate thick tissues, which can limit their use in some applications.
Applications of Cell-Based Assays
Drug discovery: Cell-based assays are used to screen large compound libraries for potential drug candidates.
Toxicity screening: Cell-based assays are used to evaluate the toxic effects of chemicals and drugs.
Basic research: Cell-based assays are used to study biological processes and mechanisms.
Disease modeling: Cell-based assays are used to model diseases in vitro, allowing for the development of new therapies.
Market Overview
The Cell-Based Assay Market is a rapidly growing industry that is expected to reach $38.23 billion by 2032, driven by increasing demand for cell-based assays in drug discovery and development, as well as the rising prevalence of chronic diseases. The market is segmented into various categories based on the type of assay, application, end user, and region. North America is currently the largest market for cell-based assays, followed by Europe and Asia-Pacific. Key players in the market include Thermo Fisher Scientific, Danaher Corporation, Merck KGaA, Promega Corporation, and Bio-Rad Laboratories. The increasing demand for personalized medicine is one of the major drivers of the cell-based assay market, as these assays enable the development of targeted therapies that are more effective and have fewer side effects.
Get a Free Sample Report - Click Here
In Conclusion,
The cell-based assay market is a rapidly growing industry that plays a critical role in drug discovery and development, as well as personalized medicine. With the increasing prevalence of chronic diseases and the need for more effective and targeted therapies, cell-based assays are becoming more and more important. The market is highly competitive, with several key players dominating the industry, offering a wide range of products and services. As the market continues to grow, it is expected to drive innovation and advancements in the field of life sciences. Overall, the cell-based assay market is poised for continued growth and success in the coming years.
Be the first person to like this.
Organ transplantation is a medical procedure that involves removing an organ from a donor and placing it into a recipient who has a damaged or failed organ. This procedure is often a last resort for patients who have exhausted all other treatment options, and it can be life-saving. However, organ transplantation is a complex and risky procedure that requires careful diagnosis, evaluation, and matching to ensure that the organ will be accepted by the recipient's body and will function properly. This is where organ transplant diagnostics come in.
Organ transplant diagnostics refers to a range of tests and procedures that are used to evaluate the compatibility of a donor organ with a potential recipient. These tests are critical in determining whether a transplant is likely to be successful, and they help to minimize the risk of rejection and other complications. There are several different types of organ transplant diagnostics, each of which plays a unique role in the transplantation process.
Blood Tests
One of the most important types of organ transplant diagnostics is blood typing. This involves testing the blood of both the donor and recipient to determine their blood type and compatibility. The most important blood group systems for organ transplantation are the ABO and Rh systems. In general, ABO compatibility is essential, and Rh compatibility is desirable but not always necessary. Other blood groups, such as the HLA system, are also important in certain cases.
In addition to blood typing, other blood tests may be performed to assess the overall health of the donor and recipient. For example, liver function tests can be used to determine whether a potential recipient is healthy enough to undergo a liver transplant, while viral load tests can be used to assess the risk of viral transmission from the donor to the recipient.
Cross-Matching
Cross-matching is another important diagnostic test that is used to assess the compatibility of a donor organ with a potential recipient. This involves mixing a small amount of the donor's blood with the recipient's blood to see if there is a reaction. If there is no reaction, the organ is considered compatible, and the transplant can proceed. However, if there is a reaction, the transplant cannot proceed, as this indicates that the recipient's immune system will likely attack the donor organ.
Cross-matching is particularly important in kidney transplantation, where a positive cross-match can lead to hyperacute rejection and the rapid loss of the transplanted kidney. In some cases, desensitization therapy can be used to reduce the risk of rejection in patients with a positive cross-match.
Imaging Tests
Imaging tests, such as ultrasound, CT scan, and MRI, are often used to evaluate the size, shape, and condition of the donor organ. These tests can help to identify any abnormalities or damage that may affect the success of the transplant. For example, an ultrasound can be used to assess the size and function of a potential liver donor, while a CT scan can be used to evaluate the condition of a potential lung donor.
In addition, imaging tests can be used to assess the recipient's anatomy and identify any potential surgical complications. For example, a CT scan can be used to evaluate the size and position of the recipient's blood vessels, which are critical for connecting the donor organ to the recipient's body.
Tissue Typing
Tissue typing, also known as histocompatibility testing, is used to assess the compatibility of a donor organ with a potential recipient at the cellular level. This involves testing the donor and recipient tissue for specific markers called human leukocyte antigens (HLAs). HLAs are proteins that are found on the surface of cells and play a critical role in the body's immune response.
In general, the more HLAs that are shared between the donor and recipient, the greater the chance of a successful transplant. However, tissue typing is a complex process that involves matching multiple HLAs and requires specialized laboratories and expertise.
Organ Transplant Diagnostics Market Overview
The Organ Transplant Diagnostics Market is expected to reach $11.78 billion by 2033, with a CAGR of 10.45% during the forecast period 2023-2033, driven by factors such as the rising prevalence of chronic diseases, increasing demand for organ transplants, and growing awareness about the importance of early diagnosis and evaluation. The market includes various diagnostic tests such as blood typing, tissue typing, cross-matching, and imaging tests, which are critical in determining the compatibility of a donor organ with a potential recipient. Key players in the market include companies such as Thermo Fisher Scientific Inc., Qiagen N.V., Illumina, Inc., and F. Hoffmann-La Roche AG, who are investing heavily in research and development to develop new and more effective diagnostic tools and techniques. As the demand for organ transplantation continues to grow, the market for organ transplant diagnostics is expected to grow as well, providing opportunities for growth and innovation in the healthcare industry.
Market Segmentation:
Segmentation 1: by Offering
Segmentation 2: by Transplant Type
Segmentation 3: by Application
Segmentation 4: by Technology
Segmentation 5: by End User
Segmentation 6: by Region
Get Free Sample Report - Click Here
Key Companies Profiled
Manufacturers
• Abbott Laboratories
• BAG Group GmbH
• bioMérieux S.A.
• Bio-Rad Laboratories, Inc.
• Eurobio Scientific
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Immucor, Inc.
• Omixon Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
Service Providers
• ARUP Laboratories
• CareDx, Inc.
• Laboratory Corporation of America Holdings
• Quest Diagnostics Incorporated
Conclusion
Organ transplant diagnostics is a critical component of the transplantation process, and it plays a vital role in ensuring the success of the transplant and minimizing the risk of complications. The diagnostic tests used in organ transplantation are complex and require specialized knowledge and expertise, and they must be performed accurately and efficiently to ensure the best possible outcomes.
Advancements in technology and research have led to significant improvements in organ transplant diagnostics over the years, and there is ongoing research to develop new and more effective diagnostic tools and techniques. With continued advances in this field, we can hope to see even more successful transplant outcomes in the future.
Be the first person to like this.
Next-generation sequencing (NGS) is a tool that is used to extract and analyze molecular information and has been able to explore the human genome in an unprecedented manner. The next-generation sequencing technology is used in basic human disease research and can be used in routine research as well.
Furthermore, the key reason to use targeted sequencing is that it is more cost-effective as compared to whole genome sequencing. This also enables deeper result analysis as compared to whole genome sequencing and other sequencing approaches. Deeper sequencing and higher depth of coverage with targeted sequencing can help avoid false interpretations of the sequencing data. This sensitivity allows targeted sequencing to provide a huge advantage of variant calling in cancer research, identification of disease mutations, gene expression studies, and signal gene disorders. Sequencing specific regions also allows one to discover causative genes and rare diseases. This focused approach allows the possibility of the use of targeted sequencing in targeted therapy applications and personalized medicine efforts.
Targeted Sequencing Market is projected to reach $10,976.1 million by 2032 from $3,198.8 million in 2022, growing at a CAGR of 13.12% during the forecast period 2022-2032. The growth in the global targeted sequencing market is expected to be driven by the increased use of targeted sequencing in clinical laboratories and diagnostic applications, especially in cancer research.
Market Lifecycle Stage
Targeted sequencing is a cost-effective and rapid way to detect novel and known variants in selected genetic or genomic regions. There are several different methods of DNA/RNA sequencing depending on the scale of the region being sequenced. Next-generation sequencing (NGS) is the most used method for targeted sequencing, which offers good scalability, speed, and resolution to evaluate the targeted regions of interest. Other methods include sanger sequencing and CRISPR.
The major advantage of targeted sequencing as compared to whole genome sequencing is the smaller and more manageable data sets created, which are significantly easier to analyze. Targeted next-generation sequencing focuses on specific genomic areas of interest, which is ideal for examining specific pathways or targeted resequencing. Furthermore, it is more rapid and cost-effective as compared to whole genome sequencing and allows deeper sequencing. This is a powerful and especially sensitive method of identifying gene mutations and variants, including rare variants.
Market Overview
Market Footprint and Growth Potential
Targeted sequencing can have many specific uses in clinical, research, pharmaceutical, etc. fields and various products like instruments, bioinformatics, consumables, and services. Till now, targeted sequencing is most widely done in research settings, which include academic and research institutions, but it is slowly transferring to diagnostic and clinical applications. Targeted sequencing is also increasingly being used by pharmaceutical and biotech companies that are working on a number of large-scale genome sequencing projects that are helping in genomics drug development programs. However, the complication being faced by pharmaceutical companies in the use of targeted sequencing is the struggle to find acceptance from stakeholders and build a commercially viable business model. This problem is mainly due to the limited clinical applications of targeted sequencing currently available.
Key Companies Profiled
• Agilent Technologies, Inc.
• Azenta US, Inc. (GENEWIZ)
• BGI Group (MGI Tech Co., Ltd.)
• CD Genomics
• Daicel Corporation (Daicel Arbor Biosciences)
• Danaher. (Integrated DNA Technologies, Inc.)
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• LGC Limited (LGC Biosearch Technologies)
• PacBio.
• PerkinElmer Inc.
• Psomagen
• QIAGEN N.V.
• Takara Bio Inc.
• Tecan Trading AG
• Thermo Fisher Scientific Inc.
• Twist Bioscience.
Get Free Sample Report - https://bisresearch.com/requestsample?id=1439&type=download
Key Questions Answered in the Report
▪ How is the targeted sequencing market revolutionizing the NGS sequencing industry?
▪ What are the major market drivers, challenges, and opportunities in the global targeted sequencing market?
▪ What are the underlying structures resulting in the emerging trends within the targeted sequencing market?
▪ How did the COVID-19 pandemic impact the global targeted sequencing market?
▪ What are the key development strategies that are being implemented by major players to sustain themselves in the market?
▪ What are the key regulatory implications in developed and developing regions pertaining to the use of targeted sequencing applications?
▪ What are the potential entry barriers that are expected to be faced by the companies willing to enter a particular region in the market?
▪ What will be the growth rate of the global targeted sequencing market during the forecast period 2022- 2032?
▪ How is each segment of the market expected to grow during the forecast period 2022-2032, and what revenue is anticipated to be generated by each of the segments?
The following are the segments:
o Product Type (Services, Kits/ Panels and Assays, Instruments, and Other Product Types)
o Target Enrichment Method (Amplicon Sequencing, Hybridization Capture, and Other Target Enrichment Methods)
o Type of Target Capture (Targeted DNA Sequencing, Targeted RNA Sequencing, and Other Types of Target Capture)
o Application (Oncology, Infectious Diseases, Cardiovascular Diseases, Reproductive Health, Rare Diseases, Neurological Disorders, Hereditary Diseases, and Other End Users)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
▪ What are the growth opportunities for the targeted sequencing companies in the region of their operation?
Additionally, BIS Research also offers a dedicated and unique platform to find and access deeptech insights and updates on emerging technologies across industry verticals. Insight Monk, an AI powered deeptech search engine, is a subscription based platform that offers a library of latest market insights and updates based on emerging tech. Learn more about InsightMonk here. https://www.insightmonk.com
Be the first person to like this.
Cancer is a complex and heterogeneous disease, and early detection is critical for improving patient outcomes. The traditional approach to cancer screening involves targeting a single type of cancer in a specific population. However, recent advances in genomic medicine and technology have paved the way for a new approach to cancer screening: multicancer screening.
Multicancer screening is a screening test that aims to detect multiple types of cancer using a single test. The goal of multicancer screening is to identify cancers at an early stage when they are more treatable, regardless of the cancer type. This approach has the potential to revolutionize cancer screening and improve patient outcomes by detecting multiple cancers at an early stage.
Multicancer Screening Market is projected to reach $7.78 billion by 2032 from $1.90 billion in 2022, growing at a CAGR of 15.09% during the forecast period 2023-2032. The growth in the global multicancer screening market is expected to be driven by the increased use of liquid biopsy testing and increasing prevalence of cancers.
There are several approaches to multicancer screening, including blood-based tests, imaging, and molecular profiling. Blood-based tests are the most promising approach to multicancer screening. These tests detect circulating tumor DNA (ctDNA) and other biomarkers in the blood that are indicative of cancer. ctDNA is released into the bloodstream by cancer cells, and it can be detected using a simple blood test. Blood-based tests can detect multiple types of cancer at an early stage, including lung, colorectal, breast, ovarian, and pancreatic cancer.
One example of a blood-based test for multicancer screening is the CancerSEEK test. CancerSEEK is a liquid biopsy test that detects ctDNA and protein biomarkers in the blood. The test can detect eight common cancer types, including ovarian, pancreatic, liver, stomach, colorectal, lung, breast, and esophageal cancer. CancerSEEK has shown promising results in early clinical trials, detecting early-stage cancers with high accuracy.
Imaging is another approach to multicancer screening. Imaging tests, such as CT scans and MRIs, can detect abnormalities in the body that may be indicative of cancer. However, imaging tests are less specific than blood-based tests, and they can lead to false positives and unnecessary follow-up tests.
Molecular profiling is another approach to multicancer screening. Molecular profiling involves analyzing the DNA and RNA of cancer cells to identify specific mutations or genetic alterations. This information can be used to develop targeted therapies for cancer treatment. Molecular profiling is most commonly used for advanced-stage cancer patients, but it has the potential to be used for early-stage cancer detection as well.
The market for multicancer screening is rapidly growing as the demand for early cancer detection and personalized medicine increases. The market is driven by factors such as increasing incidence of cancer, growing awareness about the importance of early cancer detection, and advancements in technology. Blood-based tests are expected to dominate the market due to their high sensitivity and specificity for cancer detection. North America is expected to be the largest market for multicancer screening, followed by Europe and the Asia Pacific. Major players in the multicancer screening market include Freenome, Grail, Thrive Earlier Detection, Guardant Health, Exact Sciences, and Natera, among others. The market for multicancer screening is expected to continue to grow as new technologies and approaches to cancer screening are developed and validated.
Get a Free Sample Report - Click Here
Multicancer screening has the potential to transform cancer screening and improve patient outcomes. However, there are several challenges to implementing multicancer screening on a large scale. These challenges include the high cost of screening tests, the need for more research to validate the accuracy of screening tests, and the need for guidelines to determine the appropriate age and frequency of screening.
Be the first person to like this.
The successes of cell and gene-based treatments have spurred endeavors to introduce such therapies into the market. As the need arises to cater to the clinical and commercial production of cells, coupled with the growing amount of extensive clinical data stemming from these therapies, a greater emphasis on the biomanufacturing requirement has become crucial. The high demand for the therapies is driving the growth of cell and gene therapy biomanufacturers and creating ample opportunities for them to expand in various geographies and strengthen their market presence.
Cell and Gene Therapy Biomanufacturing Market was valued at $12.31 billion in 2022 and is anticipated to reach $29.76 billion by 2031, witnessing a CAGR of 10.31% during the forecast period 2022-2031. The growth in the global cell and gene therapy biomanufacturing market is expected to be driven by the increased number of approved therapies and growing infrastructure requirements. In addition, expansion in target indications for cell and gene therapies creates a demand for large-scale biomanufacturing.
Market Lifecycle Stage
The global cell and gene therapy biomanufacturing market is in a progressing phase. The cell and gene therapy market is developing rapidly due to its potential to target chronic and rare/orphan diseases that earlier had limited treatment options. Cell and gene therapies available in the market or in the pipeline are the result of years of pioneering research. Currently, there are more than 25 cell and gene therapies approved by the FDA in the last 10 years. These factors are expected to drive the demand for consumables, equipment, and software solutions required for manufacturing cell and gene therapy, thereby augmenting the growth of the cell and gene therapy biomanufacturing market.
Moreover, manufacturers began to produce application-specific cell and gene therapy equipment in recent years.
Impact
The field of medicine is transformed with the commercialization of cell and gene therapies. With the advent of time and introduction of new technologies, cell and gene therapy areas are flourishing. There is constant ongoing research for the development of novel cell and gene therapies. According to the American Society of Gene + Cell Therapy (ASGCT), as of February 2023, there are more than 2,000 clinical trials in the pipeline. The robust clinical pipeline for novel cell and gene entities is expected to create a lucrative opportunity for manufacturers and boost the growth of the cell and gene therapy biomanufacturing market.
Key Trends
Biomanufacturing 4.0
Biomanufacturing 4.0 involves the integration of factories and supply chains through internet-connected goods and machines, which communicate with one another, gather and share data, and coordinate processes in a decentralized manner. Although biomanufacturing 4.0 is primarily implemented in high-value manufacturing sectors, the potential benefits it offers can bring to the biopharmaceutical industry, particularly in the field of cell and gene therapies. This interconnected system, driven by data, will enhance manufacturing responsiveness, resulting in more adaptable and agile biomanufacturing facilities in the future
Impact of COVID-19 on the Cell and Gene Therapy Biomanufacturing Market
Manufacturing and Supply Chains
•Interruption in manufacturing because not all necessary raw materials were available; even a single shortage of raw material can have an influence on the production of biopharmaceuticals.
•Commodity precursors like folic acid from Asia, carbon dioxide from Washington, and glassware for vials and syringes redirected for use in other sectors were no longer produced at the same scale as large portions of the industry were shut down.
Clinical Trials
•To comply with the COVID-19 response guidelines or to reallocate medical staff to the pandemic response, several clinical investigations that were unrelated to COVID-19 had to be stopped.
•According to an article published in Elsevier on April 2021, until July 2020, it was anticipated that at least 322 trials run by biopharma companies had failed. Phase II studies made up the majority of disrupted trials (44.8%), while key Phase III trials (21.7%) and early Phase I trials (26.1%) were also impacted.
Offering Treatments to Patients
•It may be more difficult to prepare for and care for patients with CGTs in a hospital setting.
•In addition to being evaluated and accredited by the Foundation for the Accreditation of Cellular Therapy, treatment facilities for CGTs must also instruct staff on how to collect, store, and ship samples. For clinical staff, this process takes a lot of time, especially during the pandemic.
Get Free Sample Report - Click Here
Key Questions Answered in the Report
What are the three potential scenarios in which the global cell and gene therapy biomanufacturing market growth can unfold during 2022-2031?
What are the impacts of COVID-19 and the Russo-Ukranian War on the global cell and gene therapy biomanufacturing market?
What are the key trends influencing the global cell and gene therapy biomanufacturing market, and what is their potential for impacting the market?
What is the patent landscape of the global cell and gene therapy biomanufacturing market like?
Which year and country witnessed the maximum patent filing between January 2020 and December 2022?
What are the key regulations that impact the growth of the global cell and gene therapy biomanufacturing market?
What are the key differences in equipment offered by key players?
What are the key drivers, restraints, and opportunities for the global cell and gene therapy biomanufacturing market?
What will be their impact on the market in short-, mid-, and long-term duration?
Which product type is projected to be the fastest-growing segment during the forecast period 2022-2031?
What is the key application for which consumables, equipment, and software solutions are utilized? Which application area is projected to be the fastest-growing segment during the forecast period 2022-2031?
Which segmentation holds the largest market share of the cell and gene therapy biomanufacturing market based on usage?
Which one of those segments is expected to be the fastest growing segment during the forecast period 2022-2031?
Who are the major end users for the cell and gene therapy biomanufacturing market? Which end user held the largest share of the market in 2021?
What are the anticipated regulatory milestones for 2023?
What is the competitive landscape in the global cell and gene therapy biomanufacturing market?
Who are the key players in the global cell and gene therapy biomanufacturing market, and what are their product offerings in the market?
Analyst View
According to Akash Mhaskar, Principal Analyst, BIS Research, “The global cell and gene therapy biomanufacturing market is strongly driven by the rising incidence of target diseases such as orphan diseases, cancers, metabolic disorders, and autoimmune disorders, among others, as well as the increasing approval of cell and gene therapies. The global cell and gene therapy biomanufacturing market has witnessed a steady growth in the number of new entrants and investments in cell and gene therapy, thereby driving a surge in demand for the consumables, equipment, and software solutions required in the manufacturing of these therapies. This trend is also expected to continue over the forecast period. Therefore, the impact of the aforementioned factors is expected to drive the global cell and gene therapy biomanufacturing market in the near future.”
Additionally, BIS Research also offers a dedicated and unique platform to find and access deeptech insights and updates on emerging technologies across industry verticals. Insight Monk, an AI powered deeptech search engine, is a subscription based platform that offers a library of latest market insights and updates based on emerging tech. Learn more about InsightMonk here. https://www.insightmonk.com
Be the first person to like this.